Antares Pharma (NASDAQ:ATRS) Rating Lowered to Hold at BidaskClub

Antares Pharma (NASDAQ:ATRS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.50 price target on shares of Antares Pharma in a research report on Monday, May 6th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $5.04.

Shares of Antares Pharma stock opened at $3.31 on Tuesday. The stock has a market cap of $539.74 million, a P/E ratio of -82.75 and a beta of 0.95. The stock’s 50 day simple moving average is $3.19 and its 200-day simple moving average is $3.10. Antares Pharma has a 1-year low of $2.53 and a 1-year high of $3.96. The company has a debt-to-equity ratio of 1.01, a current ratio of 3.46 and a quick ratio of 2.87.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The business had revenue of $28.43 million for the quarter, compared to analysts’ expectations of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. As a group, research analysts expect that Antares Pharma will post -0.08 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in ATRS. Corrado Advisors LLC purchased a new stake in shares of Antares Pharma during the 2nd quarter valued at approximately $26,000. Alpine Woods Capital Investors LLC purchased a new stake in Antares Pharma in the first quarter valued at approximately $30,000. Enterprise Bank & Trust Co purchased a new stake in Antares Pharma in the first quarter valued at approximately $45,000. Bank of Montreal Can purchased a new stake in Antares Pharma in the second quarter valued at approximately $45,000. Finally, Aperio Group LLC purchased a new stake in Antares Pharma in the second quarter valued at approximately $47,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.